{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009789","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.185351+00:00","generated_at":"2026-05-15T09:02:57.132900+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tivic reports FY2025 net loss $8.8M-$9.1M; pivots to immunotherapy with Entolimod","bullets":["Operating expenses $7.9M in 2025 vs $4.5M in 2024; net loss before disc. ops $7.9M-$8.1M.","Cash $12.6M at Dec 31, 2025 vs $2.0M at prior year-end; working capital $12.4M.","Acquired global rights to Entolimod for acute radiation syndrome; discontinued ClearUP/VNS.","CEO Michael K. Handley appointed March 2026, succeeding Jennifer Ernst.","Engaged with BARDA, DTRA, NIH, NIAID for potential Entolimod funding or procurement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009789","json":"https://secwatch.observer/filing/0001437749-26-009789.json","markdown":"https://secwatch.observer/filing/0001437749-26-009789.md","text":"https://secwatch.observer/filing/0001437749-26-009789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926009789/0001437749-26-009789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926009789/tivc20251119_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:02:57.132900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}